23156-68-5

Usage

Usage

Reducing agent, coupling reagent in biochemical and organic synthesis, synthesis of pharmaceuticals, agrochemicals, and fine chemicals

Physical form

White solid

Solubility

Soluble in water

Molecular weight

94.54 g/mol

Safety precautions

Can be harmful if ingested, inhaled, or absorbed through the skin

Upstream product

• 32380-69-1 2-(2-hydroxyethoxy)-2,3-dihydro-1H-isoindole-1,3-dione 
• 1028902-20-6 3,3-dimethylbutan-2-one O-(2-hydroxyethyl)oxime 
• 609805-97-2 tert-butyl N-(2-hydroxyethoxy)carbamate 
• 1268260-86-1 t-butyl 2-hydroxyethoxycarbamate hydrochloride 

Downstream Products

• 1093218-41-7 2-(benzylthio)-N-(2-hydroxyethoxy)nicotinamide 
• 188250-02-4 diphenylmethyl (2S,3R,5R)-3-[(2-hydroxyethoxy)imino]methyl-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate 

Relevant academic research and scientific papers

Identification of novel estrogen receptor (ER) agonists that have additional and complementary anti-cancer activities via ER-independent mechanism

In this study, a series of bis(4-hydroxy)benzophenone oxime ether derivatives such as 12c, 12e and 12h were identified as novel estrogen receptor (ER) agonists that have additional and complementary anti-proliferative activities via ER-independent mechanism in cancer cells. These compounds are expected to overcome the therapeutic limitation of existing ER agonists such as estradiol and tamoxifen, which have been known to induce the proliferation of cancer cells.

METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT.

The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of for

O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS

The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of m

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Process for Preparing 2-Aminooxyethanol

The invention relates to a process for preparing aminoglycol by reacting ketoximes with ethylene oxide under basic conditions to give a substituted 2-hydroxyethyl ketoxime and subsequently reacting the latter with an acid to give aminoglycol.

OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a colletion of diseases, disorders, and conditions associated with abnormal deposition of A-beta protei

OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.